Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AMIDEX35 Israel Fund Class A (AMDAX)

12.56
Net Asset Value
+0.32%
1 Day
+12.54%
Year-to-Date
Overall Morningstar Rating
Miscellaneous region
Style or Category
5.5
Sales Expenses
3.37%
Expense Ratio
Average
Morningstar Risk Rating™
Investment Objective The investment seeks long-term growth of capital. The fund will invest at least 95% of its net assets in the common stocks of the companies comprising the AMIDEX35™ Index, in approximately the same percentages as those companies are included in the index or until the fund's net assets reach $25 million, the Adviser may invest fund assets in a representative sample of index securities and other permissible securities. The AMIDEX35™ Index is an unmanaged index consisting of the 35 largest publicly traded Israeli companies, as measured by market capitalization. It is non-diversified.

Performance

1 month+3.46% 3 years+14.81%
3 months+4.15% 5 years+3.06%
1 year+8.28% Since inception+1.65%
Data through --

Peer Comparisonvs. Miscellaneous region

 AMDAXCategory
Performance 5-yr return+3.06%+3.00%
Expense ratio3.37%1.79%
Risk 5 year sharpe ratio0.31--
Net assets$13.7M$251.8M
Average market cap$6.6B$25.7B
Average P/E17.815.4
Portfolio turnover12%12%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyAMIDEX
Fund manager & tenureGadi Beer / 11 Years
Minimal initial investment$500.00
Minimum IRA investment$500.00

Holdings

International stock68.62%
U.S. stock30.93%
Cash0.45%
Fixed income0.00%
Other0.00%
Top 5 Sectors
Portfolio weighting
Industrial materials 27.12%
Healthcare 24.31%
Telecommunication 13.32%
Consumer goods 4.11%
Hardware 2.63%
Top 10 Holdings
Portfolio weighting
TEVA Teva Pharmaceutical11.02%
PRGO Perrigo Company PLC9.23%
CHKP Check Point Software Technologies Ltd9.07%
DOX Amdocs Ltd5.90%
ICL ICL Israel Chemicals Ltd5.72%
-- 3.95%
-- 3.88%
-- 3.67%
TARO Taro Pharmaceutical Industries Ltd3.56%
NICE Nice-Systems Ltd3.17%